Axepharma SRL
1.1 FTEThe score of Axepharma shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +51 % Total assets +53 % Headcount (avg FTE) +22 %
Accounts of the company itself (not consolidated).
The full file covers 6 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Axepharma's annual accounts
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net result | 65,629 € | ||||
| Equity | 310,130 € | ||||
| Cash | 177,525 € | ||||
| EBITDA | 101,594 € | ||||
| Total assets | 442,129 € |
Filed annual accounts
- Year ended 31 Dec 2025filed on 26 May 2026
- Year ended 31 Dec 2024filed on 01 Jul 2025
- Year ended 31 Dec 2023filed on 31 Jul 2024
- Year ended 31 Dec 2022filed on 07 Aug 2023
- Year ended 31 Dec 2021filed on 28 Jul 2022
Axepharma's financial analysis
- Solvency70.1%sector median: 44.2%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Axepharma
Axepharma's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0739.549.477
- VAT number
- BE0739549477
- Peppol
- Registered · 0208:0739549477 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 12 Dec 2019
- Registered office
- 8730 Beernem
- Size
- Micro · 1.1 FTE
- Latest accounts
- 2025 · filed on 26 May 2026
- Activity
- Retail sale of pharmaceutical products (NACE 47730)
Axepharma (SRL) has been based in Beernem since 2019, active in: retail sale of pharmaceutical products. For 2025, it reports a net profit of 65,629 € and equity of 310,130 €; its revenue is not published. With 1.1 full-time equivalents, it is a micro-enterprise by headcount. Its solvency stands at 70.1%, above the median of its sector (44.2%).
Companies similar to Axepharma
Companies in the same business, of comparable size and area, outside its group.
- Smalle - Gheleyns Retail sale of pharmaceutical products Bruges · balance sheet 446,568 €
- Apoteek BEK Retail sale of pharmaceutical products Antwerp · balance sheet 441,724 €
- Apotheek Boel Retail sale of pharmaceutical products Aalst · balance sheet 442,849 €
- Pharmacie Querton Retail sale of pharmaceutical products Anderlecht · balance sheet 442,937 €
- DE Carne Koen Retail sale of pharmaceutical products Oosterzele · balance sheet 429,003 €
- Nivelpharma Retail sale of pharmaceutical products Nivelles · balance sheet 440,169 €
- Medsam Retail sale of pharmaceutical products Etterbeek · balance sheet 439,586 €
- APO Casdan Retail sale of pharmaceutical products Schoten · balance sheet 436,566 €
Frequently asked questions about Axepharma
What is the revenue of Axepharma?
Axepharma files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Axepharma?
In Belgium, the VAT number is the company number prefixed with BE: BE0739549477 for Axepharma, if the company is VAT-registered. Its company number (CBE) is 0739.549.477.
Where is the registered office of Axepharma?
According to the CBE register, the registered office of Axepharma is in 8730 Beernem.
What is the equity of Axepharma?
At the close of the 2025 financial year, the equity of Axepharma amounts to 310,130 €, a solvency of 70.1% of total assets.
How many people work at Axepharma?
1.1 full-time equivalents on average according to the 2025 social balance sheet.
Who manages Axepharma?
The register lists 2 active mandates at Axepharma. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Axepharma
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →